Evidence- and data-driven classification of low back pain via artificial intelligence: Protocol of the PREDICT-LBP study.

In patients presenting with low back pain (LBP), once specific causes are excluded (fracture, infection, inflammatory arthritis, cancer, cauda equina and radiculopathy) many clinicians pose a diagnosis of non-specific LBP. Accordingly, current management of non-specific LBP is generic. There is a need for a classification of non-specific LBP that is both data- and evidence-based assessing multi-dimensional pain-related factors in a large sample size. The "PRedictive Evidence Driven Intelligent Classification Tool for Low Back Pain" (PREDICT-LBP) project is a prospective cross-sectional study which will compare 300 women and men with non-specific LBP (aged 18-55 years) with 100 matched referents without a history of LBP. Participants will be recruited from the general public and local medical facilities. Data will be collected on spinal tissue (intervertebral disc composition and morphology, vertebral fat fraction and paraspinal muscle size and composition via magnetic resonance imaging [MRI]), central nervous system adaptation (pain thresholds, temporal summation of pain, brain resting state functional connectivity, structural connectivity and regional volumes via MRI), psychosocial factors (e.g. depression, anxiety) and other musculoskeletal pain symptoms. Dimensionality reduction, cluster validation and fuzzy c-means clustering methods, classification models, and relevant sensitivity analyses, will classify non-specific LBP patients into sub-groups. This project represents a first personalised diagnostic approach to non-specific LBP, with potential for widespread uptake in clinical practice. This project will provide evidence to support clinical trials assessing specific treatments approaches for potential subgroups of patients with non-specific LBP. The classification tool may lead to better patient outcomes and reduction in economic costs.

Informations de copyright

Copyright: © 2023 Belavy et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

DLB, ST, MT, LS, SeS, HJW, MA, GT, KE, BF, JVO, CTM, PJO, SB, RD, SK declare no conflicts of interest. BB: declares no conflicts of interest relevant to the current work, but has previously received research support, consultancy fees and/or honoraria from AbbVie, Amgen, Biogen, GE/Lunar, Janssen, Galapagos, Gilead, Medimaps, MSD, Sanofi Genzyme, Theramex, UCB. TS: declares prior consulting fees from Johnson & Johnson, Amgen, Kaia Health Software, SpineArt, Implantcast and speaking and travel arrangements from Johnson & Johnson, ICOTEC, Nuvasive, Ulrichmedical, Silony, Amgen, Kaia Health Software. EE-K has received fees from painCert GmbH, Casquar GmbH and Omega Pharma GmbH, outside the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials.